Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel

Terry K.W. Ma, Yat Yin Lam, Victoria P. Tan, Thomas J. Kiernan, Bryan P. Yan

Research output: Contribution to journalReview articlepeer-review

Abstract

Dual antiplatelet therapy with aspirin and clopidogrel has been shown to reduce subsequent cardiac events in patients with acute coronary syndrome or coronary artery stenting. Clopidogrel, a thienopyridine, is a prodrug that is transformed in vivo to an active metabolite by the cytochrome P450 (CYP) enzyme system. The genes encoding CYP enzymes are polymorphic. Recent data demonstrated patients carrying a genetic variant of CYP enzymes (e.g. CYP2C19) would have a higher rate of ischemic events than non-carriers due to an attenuation of the pharmacokinetic and pharmacodynamic responses to clopidogrel. Furthermore, concomitant gastrointestinal ulcer prophylaxis with a proton pump inhibitor (PPI) is commonly prescribed to patients because of the increased risk of bleeding with dual antiplatelet therapy. PPIs are extensively metabolized by the cytochrome P450 system and have been associated with decreased antiplatelet activity of clopidogrel. In this review, we will discuss the impact of CYP450 enzymes genetic variation and CYP450 pathway drug-drug interactions in pharmacological and clinical response to clopidogrel.

Original languageEnglish
Pages (from-to)249-259
Number of pages11
JournalPharmacology and Therapeutics
Volume125
Issue number2
DOIs
Publication statusPublished - Feb 2010
Externally publishedYes

Keywords

  • Clopidogrel
  • Cytochrome P450
  • Polymorphism
  • Proton pump inhibitor

Fingerprint

Dive into the research topics of 'Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel'. Together they form a unique fingerprint.

Cite this